A study conducted on nearly 6,000 patients demonstrated the importance of endocrine treatment and a drug in treating breast cancer.
Scientists from the Biosanitary Institute of Granada in southern Spain, led by Isabel Blancas Lopez Barajas and Sergio Granados, participated in this research. The results were published in the Annals of Oncology. They have been involved in an international clinical trial.
The study results have shown that combining endocrine treatment with Abemaciclib (a breast cancer drug) is a better treatment for high-risk cancers in their early stages. Patients also perceive it as a safer one. Initials.
Researchers from IBS GRANADA, San Cecilio Clinical University Hospital, and the University of Granada have participated in this international study. It is a phase three clinical trial involving almost six thousand participants from different countries.
The 27-month study compared patients receiving hormonal therapy and Abemaciclib to see if there were any adverse effects.
International study confirms the effectiveness of endocrine treatment against cancer.
In previous studies, combined hormonal and drug therapy has improved the invasive disease-free survival of patients with high-risk estrogen receptor-positive breast cancer.
Researchers have analyzed adverse effects, their clinical management, and the outcome of these adverse effects in patients who took the drug. They also analyzed their perception of the quality of their life based on symptoms, and other variables, such as their weight. These adverse effects.
The results show that although combining a drug with an endocrine treatment may increase the risk of adverse reactions, it does not mean that patients will suffer from more clinical complications.
The adverse effects were more severe in the group receiving the drug. However, these were problems that were detected only in blood tests. They were not clinically significant and could be managed and reversed using medication.